Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
brief summary
This Phase IV, open-label, multicenter roll-over study evaluated the long-term safety of imatinib in patients who had completed a previous Novartis-sponsored imatinib study and were considered by the investigator to continue benefiting from treatment.
detailed description
There was no screening period. After providing informed consent and meeting the eligibility criteria, patients entered the study directly from their parent study. The starting imatinib dose was the same as the dose received in the parent study and could subsequently be adjusted based on the investigator's clinical judgment.
Patient evaluations were recommended every 12 weeks, with a permitted window of plus or minus 1 week. Evaluations could be conducted on site or remotely at the investigator's discretion. At each scheduled evaluation, the investigator confirmed whether the patient continued to derive clinical benefit and could remain on study treatment. Patients returned to the study center every 24 weeks, with a permitted window of plus or minus 1 week, for resupply of study medication, unless otherwise managed according to local practice.
Patients continued treatment until they no longer derived clinical benefit, developed unacceptable toxicity, withdrew consent, did not comply with the protocol, discontinued based on the investigator's judgment, died, or transferred to commercial supply in accordance with applicable country requirements.
Adverse events and serious adverse events were collected throughout the treatment period. After the last dose of study treatment, patients were followed for safety for 30 days. The study ended after all patients had completed their final protocol-required assessment.
official title
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment